Epiloid Biotechnology

What Epiloid Biotechnology does

Epiloid Biotechnology Inc. is a Toronto, Canada-based contract research organization founded in 2022 that provides preclinical neurological drug testing services using lab-grown human brain organoids. The company's core technology is its three-dimensional human brain organoid platform, designed to more accurately mimic human brain function compared to traditional preclinical models such as animal testing or 2D cell cultures. Epiloid structures its offering into three interconnected product lines: Organoids (the lab-grown brain tissue products), Services (drug testing performed using those organoids), and Predictions (drug efficacy and toxicity prediction reports), positioning the platform as an alternative to animal models in early-stage CNS drug development.

The company targets pharmaceutical and biotechnology companies developing neurological drugs, addressing the well-documented attrition problem in CNS pipelines — fewer than 6% of neurology drugs reach market, and failed candidates can cost $0.8-1.6 billion each. Epiloid claims its organoid-based approach delivers 5x more predictable preclinical readouts than traditional models. It operates a B2B enterprise sales motion, generating revenue through professional services contracts with drug developers, with pricing not publicly disclosed and obtained through direct inquiry. Operating geography is limited to Ontario, with no global footprint claim; current scale is 1-10 employees with no disclosed customers or revenue.

The capital structure is non-dilutive and grant-driven: cumulative disclosed funding totals approximately $180,000 CAD-equivalent across four acceptances — The LAUNCH program (June 2023), the Center of Aging and Brain Health Innovation (March 2025), the Ontario Brain Institute's Centre for Analytics (March 2026, $80K CAD, providing access to NeuroFL and Brain-CODE data assets), and Merck's Digital Sciences Studio accelerator cohort (March 2026, $100K USD from Merck Global Health Innovation Fund, The Venture Collective, and CQDM). No equity financing, patents, named customers, or management team details are disclosed in available sources.

Name

Epiloid Biotechnology

Legal name

Epiloid Biotechnology Inc.

Website

https://epiloid.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Epiloid Biotechnology is a Toronto-based contract research organization founded in 2022 that provides preclinical neurological drug testing services using lab-grown human brain organoids to pharmaceutical and biotechnology companies developing CNS drugs.

Ownership category

akta.pro rank

Product category

Preclinical Drug Testing Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)

akta.pro secondary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• Contract research services
• Brain organoid testing
• Neurological drug testing
• Preclinical drug screening
• Organoid technology

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Preclinical Drug Testing Services: The company provides preclinical testing services to pharmaceutical and biotech companies developing neurological drugs, using human brain organoids to predict drug outcomes before clinical trials. Revenue appears to come from service contracts with drug development companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Epiloid Biotechnology is a contract research organization that provides preclinical neurological drug testing services using lab-grown human brain organoids. Its three offerings — Organoids (the lab-grown human brain tissue products), Services (drug testing using these organoids), and Predictions (drug efficacy/toxicity predictions) — are sold to pharmaceutical and biotechnology companies developing neurological drugs as a more predictable alternative to traditional preclinical models, with claimed 5x more predictable outcomes.

Product overview

Epiloid Biotechnology is a preclinical neurological drug testing company that uses lab-grown human brain organoids as its core technology. The company offers three interconnected offerings: Organoids (the lab-grown human brain tissue products), Services (drug testing using these organoids), and Predictions (drug efficacy and toxicity predictions). Their organoid-based approach is claimed to be 5 times more predictable than traditional preclinical models, helping reduce drug failures, lower development costs, and accelerate effective treatments for neurological conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Organoids Lab-grown human brain organoids used for preclinical neurological drug testing, designed to mimic human brain function and predict drug effectiveness and toxicity for pharmaceutical and biotechnology customers.
• Services Preclinical neurological drug testing services leveraging lab-grown human brain organoids to provide drug efficacy and toxicity predictions for pharmaceutical and biotechnology companies developing neurological drugs.
• Predictions Drug efficacy and toxicity prediction services using human brain organoid models to inform preclinical drug development decisions for pharmaceutical and biotechnology customers.

Quantifiable outcome

• 5x more predictable preclinical neurological drug testing
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Ontario Brain InstitutecoreStrategic or Co-development Partner · 19 March 2026Ontario Brain Institute invested $640,000 in eight new research projects through its Centre for Analytics, with Epiloid Biotechnology as one of the project leaders using AI, federated learning, and secure data analytics for brain health research. Epiloid participates in research initiatives focused on neurological conditions using OBI's NeuroFL federated learning platform and Brain-CODE data assets.
• Merck Digital Sciences StudiocoreGTM or Marketing Partner · 13 March 2026Epiloid Biotechnology was selected for the second cohort of Merck's Digital Sciences Studio accelerator in Montreal, Canada, scheduled to begin March 2026. The nine-month program provides $100,000 USD in funding from Merck Global Health Innovation Fund, The Venture Collective, and CQDM, along with mentorship from Merck and operating partner Centech.

Scale indicators1 record

Recent moves2 records

Expansion highlights3 records

Emerging players

• bit.bio: bit.bio provides iPSC-derived human cell types (including neural cells) for drug discovery and research, supplying pharma with consistent, defined neural cell products. It is an emerging player whose iPSC-derived neural offerings could be supplied to or compete with Epiloid's organoid services.
• Cypre (previously Pershing Biosciences): Cypre provides 3D patient-derived tumor and tissue models for drug screening and preclinical research. While its current focus is oncology, its 3D model platform and CRO services overlap with Epiloid's approach to in vitro disease modeling.

Direct peers

• Hubrecht Organoid Technology (HUB): HUB is the foundational organoid technology holder spun out of the Hubrecht Institute, providing organoid biobanking, licensing, and preclinical testing services to pharma. As the origin of the Lgr5+ organoid IP and an active CRO, it sets the competitive benchmark Epiloid must differentiate against.
• Crown Bioscience (JSR Life Sciences): Crown Bioscience is a global preclinical CRO with oncology and immuno-oncology focus, expanding into organoid and PDX-based services for drug discovery. It competes for the same pharma R&D testing budgets and offers more comprehensive in vivo/3D model portfolios.
• Mimetas: Mimetas offers organ-on-chip platforms (OrganoPlate) for compound screening, toxicology, and disease modeling used by pharma. Comparable to Epiloid as a specialized organ-on-chip / 3D model CRO targeting preclinical decision-making.
• Emulate Inc. Emulate develops organ-on-chip technology (Liver-Chip, Brain-Chip) and provides preclinical testing services and instruments to pharma. The Brain-Chip offering makes it a direct comparable for neurological organoid/on-chip preclinical testing.
• NeuCyte: NeuCyte develops iPSC-derived neural cell models and 3D neural cultures for neurodegenerative and epilepsy drug discovery. It is a direct peer focused on the same neurological in vitro testing niche, with overlapping customers in CNS pharma.
• CN Bio Innovations: CN Bio provides organ-on-chip and microphysiological systems for preclinical drug testing, including liver, lung, and CNS models, sold to pharma R&D. It directly competes in the human-relevant in vitro preclinical testing market Epiloid targets.
• InSphero: InSphero is a contract research organization specializing in 3D cell-based models (organoids and spheroids) for preclinical drug discovery, including neurotoxicity and disease modeling. It is the closest direct peer to Epiloid given its organoid-focused CRO model serving pharma.

Broad incumbents

• Charles River Laboratories: Charles River is a large preclinical CRO offering safety assessment, neurology models, and increasingly organoid-based services. It is a broad incumbent that competes for the same enterprise neurology preclinical budgets as Epiloid.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/epiloid-biotechnology
• Xx.com/EpiloidBio

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epiloid Biotechnology